title: Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo.
authors: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
authors: Paul
authors: P
authors: Emery
authors: Institute of Rheumatology, Prague, Czech Republic.
authors: Jiří
authors: J
authors: Vencovský
authors: Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.
authors: Jeehoon
authors: J
authors: Ghil
authors: Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.
authors: Soo Yeon
authors: SY
authors: Cheong
authors: Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.
authors: Young Hee
authors: YH
authors: Rho
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G
chemical_list: D007074:Immunoglobulin G; D000068800:Etanercept
keywords: Disease Activity; Infections; Treatment